As the United States undertakes historic adjustments to its immunization schedules, an unexpected name has emerged in a surprising turn: Høeg, a US-based sports physician and epidemiologist who initially gained attention by questioning Covid vaccines throughout the pandemic and has zeroed in on possible deaths after Covid immunization in her recent time at the FDA.
Public health authorities had intended to unveil radical revisions to the childhood vaccination calendar earlier this month, bringing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of alignment with many the global community with no evidence for public health gain. The announcement has been postponed until the new year.
Instead of the top vaccines chief, Høeg is set to present at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this year.
Høeg's temporary position could signify a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.
Høeg has repeatedly called for halting some childhood shot schedules in the US so as to align more similar to the Danish model, a nation with nationalized medicine and a population approximately the size of the state of Wisconsin.
To date comments, she has kept her attention on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.
Dr. Høeg has no obvious track record in pharmaceutical research, approval processes or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.
“It seems she lacks to have the necessary background” for leading the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in managing a major agency. She lacks background in drug approvals.”
Former directors of CBER would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who ran the center have had.”
This division has an enormous portfolio at the agency, she emphasized.
“The public just focuses on the novel medication approvals, but the off-patent medication office authorizes numerous generic drugs. There’s a biosimilars division, over-the-counter program and more, and each of these need to be managed,” Woodcock said. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”
Furthermore, a substantial leadership component to the job, which manages more than 5,000 employees. “It’s a massive management job, if you perform it correctly,” Woodcock concluded.
In response to questions about Høeg’s qualifications and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a representative stated that the “questions rely on incorrect assumptions”.
“This background aligns with the responsibilities of her job,” the spokesperson stated, citing the months Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.
As the temporary head, Dr. Høeg takes over the agency head's controversial expedited review system, a contentious rapid drug-approval program that allegedly troubled her preceding directors. “How are these therapies being selected for this expedited pathway? Who is making the decisions?” Howard questioned. “There is a lot of lack of transparency occurring at the FDA right now.”
In general, he said, “the FDA looks to be trending towards less stringent rules of pharmaceuticals, with the exception of immunizations.”
Concerning vaccines, Høeg has a more established, if problematic, history, Howard have noted. She released a research paper using non-validated public submissions to estimate the rate of myocarditis after Covid vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are pose a greater threat than they are.
Part of her “policy goals” for the incoming federal leadership encompassed altering guidelines for new vaccines and discontinuing “non-essential” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has allegedly suggested excluding young men from obtaining COVID-19 vaccines.
“She is an all-around ideologue who starts off with her preconceived notions and tailors the evidence to accommodate the data in a extremely deceptive, fraudulent fashion,” Howard stated.
Dr. Høeg aligned with other skeptics, {like|
A seasoned gambling analyst with over a decade of experience in casino gaming and slot machine strategy development.
